Eos Energy Enterprises Inc vs BIO-TECHNE Corp — how do they compare? Eos Energy Enterprises Inc trades at $2.81 (market cap $1.13B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 10.1× Eos Energy Enterprises Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and BIO-TECHNE Corp for 63 Days on average.
| EOSE | TECH | |
|---|---|---|
Market Cap | $1.13B | $11.37B |
Volume | 17,918,777 | 3,153,511 |
Sector | Industrials | Health |
52-Week High | $19.19 | $72.61 |
52-Week Low | $2.77 | $43.31 |
Typical Hold Time | 16 Days | 63 Days |
Enterprise Value | $1.47B | $11.40B |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $3.10, down 4.91% on the day, with a bearish technical signal from moving averages. The company is in a high-growth phase, with revenue surging from $114.20 million in 2025 to $214 million in 2026, though it remains deeply unprofitable with a net income margin of -246.76%. Recent positive developments include a major partnership with Google and a $87 million Department of Energy loan advance to expand production capacity.
The outlook is a mix of high growth potential and significant financial risk. Analyst consensus is a 'Buy' with a $7.10 price target, implying substantial upside, but the stock carries execution risk as the company burns cash to scale. Investors are betting on EOSE capturing market share in long-duration energy storage, but must tolerate volatility and ongoing losses.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →